Skb410

4 trials 4 recruiting

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

4 Recruiting

0 Completed trials

1 Sponsors

9 Countries

Phase I/II

Phase I (FiH)

Phase I/II: 3 Phase I (FiH): 1

Indications tested

Carcinoma in situ 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 4

All trials

4 total

A clinical study of MK-3120 in people with bladder cancer (MK-3120-003) Recruiting

2025-520467-40-00 Phase I/II 8 countries Merck Sharp & Dohme LLC
A clinical study of new treatments given with enfortumab vedotin and pembrolizumab in people with urothelial cancer (MK-3475-04D) Recruiting

2025-522253-19-00 Phase I/II 3 countries Merck Sharp & Dohme LLC
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1… Recruiting

2023-506384-34-00 Phase I (FiH) 4 countries Merck Sharp & Dohme LLC
A clinical study of MK-3120 in people with solid tumors (MK-3120-002) Recruiting

2024-516817-19-00 Phase I/II 3 countries Merck Sharp & Dohme LLC

Showing 1–4 of 4 trials

← All drugs A–Z